CD38 and Waldenstrom macroglobulinemia: A considerable amount of malignant clone of plasma cells in Waldenström macroglobulinemia patients expresses CD38 (40–70%) [49,50,51], explaining the rationale for a recently completed clinical trial to treat Waldenström macroglobulinemia patients with daratumumab [52].